Cargando…
The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
The human immunodeficiency virus (HIV-1) poses a serious risk to global public health. The development of a safe and effective vaccine could stop the HIV/AIDS pandemic. Much of the research focused on HIV-1 prevention through vaccination is aimed at developing immunogens and immunization strategies...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
A.I. Gordeyev
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826149/ https://www.ncbi.nlm.nih.gov/pubmed/31720017 http://dx.doi.org/10.32607/20758251-2019-11-3-56-65 |
_version_ | 1783465025275428864 |
---|---|
author | Rudometov, A. P. Rudometova, N. B. Shcherbakov, D. N. Lomzov, A. A. Kaplina, O. N. Shcherbakova, N. S. Ilyichev, A. A. Bakulina, A. Yu. Karpenko, L. I. |
author_facet | Rudometov, A. P. Rudometova, N. B. Shcherbakov, D. N. Lomzov, A. A. Kaplina, O. N. Shcherbakova, N. S. Ilyichev, A. A. Bakulina, A. Yu. Karpenko, L. I. |
author_sort | Rudometov, A. P. |
collection | PubMed |
description | The human immunodeficiency virus (HIV-1) poses a serious risk to global public health. The development of a safe and effective vaccine could stop the HIV/AIDS pandemic. Much of the research focused on HIV-1 prevention through vaccination is aimed at developing immunogens and immunization strategies to induce the formation of antibodies with neutralizing activity against a broad range of HIV-1 isolates (bNAbs). The objective of this study was to develop immunogens capable of targeting an immune response to MPER, one of the regions of bNAb binding in Env. Two immunogens carrying MPER fragments on their scaffolds (protein YkuJ Bacillus subtilis and artificial polypeptide TBI) were constructed. Circular dichroism spectroscopy was used to show that the secondary structure of the immunogens was consistent with their theoretical models. The antigenic structure of the MPER-TBI and YkuJ-MPER proteins was characterized using bNAbs that recognize HIV-1 MPER (2F5, 4E10, and 10E8). The rabbit model made it possible to show the immunogenicity of the constructed recombinant proteins. The resulting serum was found to be cross-reactive with immunogens carrying MPER. The constructs designed and characterized in this study can be used for targeting the humoral immune response to MPER, which is known to be one of the sites of HIV-1 vulnerability. |
format | Online Article Text |
id | pubmed-6826149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | A.I. Gordeyev |
record_format | MEDLINE/PubMed |
spelling | pubmed-68261492019-11-12 The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites Rudometov, A. P. Rudometova, N. B. Shcherbakov, D. N. Lomzov, A. A. Kaplina, O. N. Shcherbakova, N. S. Ilyichev, A. A. Bakulina, A. Yu. Karpenko, L. I. Acta Naturae Research Article The human immunodeficiency virus (HIV-1) poses a serious risk to global public health. The development of a safe and effective vaccine could stop the HIV/AIDS pandemic. Much of the research focused on HIV-1 prevention through vaccination is aimed at developing immunogens and immunization strategies to induce the formation of antibodies with neutralizing activity against a broad range of HIV-1 isolates (bNAbs). The objective of this study was to develop immunogens capable of targeting an immune response to MPER, one of the regions of bNAb binding in Env. Two immunogens carrying MPER fragments on their scaffolds (protein YkuJ Bacillus subtilis and artificial polypeptide TBI) were constructed. Circular dichroism spectroscopy was used to show that the secondary structure of the immunogens was consistent with their theoretical models. The antigenic structure of the MPER-TBI and YkuJ-MPER proteins was characterized using bNAbs that recognize HIV-1 MPER (2F5, 4E10, and 10E8). The rabbit model made it possible to show the immunogenicity of the constructed recombinant proteins. The resulting serum was found to be cross-reactive with immunogens carrying MPER. The constructs designed and characterized in this study can be used for targeting the humoral immune response to MPER, which is known to be one of the sites of HIV-1 vulnerability. A.I. Gordeyev 2019 /pmc/articles/PMC6826149/ /pubmed/31720017 http://dx.doi.org/10.32607/20758251-2019-11-3-56-65 Text en Copyright ® 2019 National Research University Higher School of Economics. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rudometov, A. P. Rudometova, N. B. Shcherbakov, D. N. Lomzov, A. A. Kaplina, O. N. Shcherbakova, N. S. Ilyichev, A. A. Bakulina, A. Yu. Karpenko, L. I. The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites |
title | The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites |
title_full | The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites |
title_fullStr | The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites |
title_full_unstemmed | The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites |
title_short | The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites |
title_sort | structural and immunological properties of chimeric proteins containing hiv-1 mper sites |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826149/ https://www.ncbi.nlm.nih.gov/pubmed/31720017 http://dx.doi.org/10.32607/20758251-2019-11-3-56-65 |
work_keys_str_mv | AT rudometovap thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT rudometovanb thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT shcherbakovdn thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT lomzovaa thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT kaplinaon thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT shcherbakovans thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT ilyichevaa thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT bakulinaayu thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT karpenkoli thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT rudometovap structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT rudometovanb structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT shcherbakovdn structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT lomzovaa structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT kaplinaon structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT shcherbakovans structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT ilyichevaa structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT bakulinaayu structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites AT karpenkoli structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites |